by Hua Zhang, Lianmin Zhang, Kaikai Zhu, Bowen Shi, Yuesong Yin, Jinfang Zhu, Dongsheng Yue, Bin Zhang, Changli Wang Introduction The aim of this study was to investigate the prognostic significance of the combination of the preoperative platelet ... Plosone.org, 3 weeks ago
1 images for "lymphocyte count"
Researchers from Wonkwang University Describe Findings in Gastric Cancer (Absolute monocyte and lymphocyte count prognostic score for patients with...
Researchers from Wonkwang University Describe Findings in Gastric Cancer (Absolute monocyte and lymphocyte count prognostic score for patients with gastric cancer) By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on ...4 Traders, 1 month ago
Acute Transient Global Ventricular Dysfunction As the Presenting Symptom of Anaplastic Large-Cell Lymphoma [DIAGNOSIS IN ONCOLOGY]
A 36-year-old man presented to the hospital with a 4-day history of fever, sore throat, perspiration, dyspnea, and generalized myalgia. He had no relevant past medical problems, nor history of illicit drug use. On arrival, he was hemodynamically ...Journal of Clinical Oncology, 1 week ago
Novartis announces Phase III study of Arzerra® met primary endpoint of improved progression-free survival in patients with relapsed CLL
Positive top-line results seen with Arzerra plus fludarabine and cyclophosphamide in chronic lymphocytic leukemia (CLL) patients when initial treatment stopped working CLL is the most commonly diagnosed adult leukemia in Western countries, ...Biotechgate, 1 month ago Genmab Announces Phase III Study of Arzerra(r) Met Primary Endpoint of Improved Progression-Free Survival in Patients with Relapsed CLL Yahoo! Finance, 1 month ago Genmab A/S : Announces Phase III Study of Arzerra® Met Primary Endpoint of Improved Progression-Free Survival in Patients with Relapsed CLL 4 Traders, 1 month ago Novartis : announces Phase III study of Arzerra® met primary endpoint of improved progression-free survival in patients with relapsed CLL» 4 Traders, 1 month ago
Scanning electron micrograph of HIV-1 budding (in green) from cultured lymphocyte. (Image courtesy of the Centers for Disease Control and Prevention's Public Health Image Library. Photo Credit: C. Goldsmith, Content Providers: CDC/ C. Goldsmith, P.Metro Weekly, 1 day ago
Abstract CD47 is a widely expressed receptor that regulates immunity by engaging its counter-receptor SIRPα on phagocytes and its secreted ligand thrombospondin-1. Mice lacking CD47 can exhibit enhanced or impaired host responses to bacterial ...Plosone.org, 3 days ago
Television host/producer Marc Summers has plenty to be thankful for. Diagnosed with lymphocytic leukemia in 2010, Summers did two years of chemo, is in remission and "feels like a million bucks." That's good because he's crazy busy executive ...Metro.us, 3 days ago
Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm
Abstract This randomized, double-blind, placebo-controlled, 6-arm, parallel-design study investigated cardiac and hematological pharmacodynamic effects of ceralifimod (ONO-4641), a selective sphingosine-1-phosphate (S1P) receptor modulator, over a ...Journal of Clinical Pharmacology, 4 days ago
New ibrutinib (IMBRUVICA®) Data to be Showcased at American Society of Clinical Oncology (ASCO) Annual Meeting
IMBRUVICA Combination Data in Chronic Lymphocytic Leukemia to be Featured in Official ASCO Press Program SUNNYVALE, Calif., May 13, 2015 /PRNewswire/ — Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that ibrutinib (IMBRUVICA(®)) ...Red Orbit, 2 weeks ago European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) to Treat.. ADVFN India, 1 week ago Pharmacyclics Release: European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA (ibrutinib) To Treat Waldenstrom's Macroglobulinemia BioSpace, 1 week ago Pharmacyclics (PCYC) Release: European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA (ibrutinib) To Treat Waldenstrom's Macroglobulinemia 5/22/2015 ClinicSpace, 1 week ago
More from: BioSpace, Town Hall...and 46 other sources
Contributions of T Lymphocyte Abnormalities to Therapeutic Outcomes in Newly Diagnosed Patients with Immune Thrombocytopenia
T cell abnormalities have been reported to play an important role in pathogenesis of immune thrombocytopenia (ITP) besides specific autoantibodies towards platelet. The aim of this study was to explore the clinical importance of T lymphocyte subsets ...Bionity.com, 1 week ago
on your WebpageAdd Widget >Get your members hooked!